Sagent Pharmaceuticals

Sagent Pharmaceuticals focuses on the development and commercialization of injectable pharmaceutical products for cancer, oncology and urology. Read more

Peter Kaemmerer's photo - CEO of Sagent Pharmaceuticals

CEO

Peter Kaemmerer

CEO Approval Rating

68/100

Est. Annual Revenue
Est. Employees
Sector

Update Industry

SAGENT PHARMACEUTICALS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Bausch Health is perceived as one of Sagent Pharmaceuticals's biggest rivals. Bausch Health was founded in 1960, and its headquarters is in Laval, Quebec. Bausch Health competes in the Health Care Supplies field. Bausch Health has 21,160 more employees than Sagent Pharmaceuticals.

Sun Pharma is one of Sagent Pharmaceuticals's top rivals. Sun Pharma is a Public company that was founded in 1983 in Mumbai, Maharashtra. Sun Pharma operates in the Pharmaceuticals industry. Compared to Sagent Pharmaceuticals, Sun Pharma has 29,560 more employees.

Sandoz is Sagent Pharmaceuticals's #3 rival. Sandoz is a Private company that was founded in Holzkirchen, Bavaria in 1886. Sandoz is in the Pharmaceuticals industry. Sandoz has 26,060 more employees vs. Sagent Pharmaceuticals.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $297.8M a good estimate for Sagent Pharmaceuticals's revenue?

Sagent Pharmaceuticals Acquisitions

No recent acquisitions found related to Sagent Pharmaceuticals

Sagent Pharmaceuticals Funding History

Since Sagent Pharmaceuticals was founded in 2006, it has participated in 3 rounds of funding. In total Sagent Pharmaceuticals has raised $162.0M. Sagent Pharmaceuticals' last funding round was on Apr 2011 for a total of $92.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Apr 2011
$92M

Series B
Apr 2010
$40M
-
Series A
Jun 2009
$30M

Vivo Ventures

Since Sagent Pharmaceuticals was founded in 2006, it has participated in 3 rounds of funding. In total Sagent Pharmaceuticals has raised $162.0M. Sagent Pharmaceuticals' last funding round was on Apr 2011 for a total of $92.0M

Sagent Pharmaceuticals Investments

No recent investments found related to Sagent Pharmaceuticals

Sagent Pharmaceuticals News

May 2, 2019PharmaTech

Sagent Pharmaceuticals, Inc. Recalls Ketorolac Tromethamine Injection, USP, 60mg/2mL

Sagent Pharmaceuticals, Inc. announced on April 30 that it was voluntarily recalling one lot of Ketor... See more »
May 2, 20199News

Anti-inflammatory drug recalled for blood infection risk

Adults who take Sagent's recalled Ketorolac Tromethamine Injection could potentially develop sepsis, ... See more »
March 12, 2019BioPortfolio

Sagent acquires US facility with an eye on future biosimilar products

Sagent purchases Xellias FDAapproved site in North Carolina which has capabilities to manufacture bot... See more »
March 4, 2019FiercePharma

Sagent buys U.S. sterile injectables plant in boost for parent Nichi-Iko

Japan's Nichi-Iko Pharmaceutical bought Illinois-based Sagent Pharmaceuticals in 2016 to get a footho... See more »
March 4, 2019BioPortfolio

Sagent Pharmaceuticals announces acquisition of Raleigh manufacturing site

Financial terms of the transaction have not been disclosed. The manufacturing site which is approved ... See more »
March 4, 2019The Business Journals: Raleigh/Durham

Raleigh pharmaceutical production facility acquired

A Xellia Pharmaceuticals production site in north Raleigh has been sold to an Illinois pharmaceutical... See more »
March 1, 2019Manufacturing Chemist

Xellia divests North Carolina production facilities to Sagent Pharmaceuticals

Xellia Pharmaceuticals has entered into an agreement to divest its Raleigh, North Carolina manufactur... See more »

Sagent Pharmaceuticals Blogs

Sagent Pharmaceuticals Press Releases

September 28, 2017EIN Presswire

Marketing Approval for Infliximab Biosimilar 100mg "Nichi-Iko" in Japan

Sagent Pharmaceuticals Announces U.S. Infliximab Phase III Study UnderwaySCHAUMBURG, ILLINOIS, UNITED... See more »
April 12, 2017Blackbird

Global Bupivacaine HCl Market 2017 - Sagent Pharmaceuticals

Pune, Mahrashtra - (SBWIRE) - 04/13/2017 - The motive of this strategic research report entitled Glob... See more »
August 8, 2016Business Wire

Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.

TOKYO--(BUSINESS WIRE)--Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) ("Nichi-Iko" or "Parent") and ... See more »
July 18, 2016Business Wire

Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional C... See more »
June 29, 2016PR-Inside

"Sagent Pharmaceuticals, Inc." is now available at Fast Market Research

(PR-inside.com) Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Inves... See more »

Sagent Pharmaceuticals Videos

February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852046635741294" on VIMEO

Cast: Sagent Pharmaceuticals... See more »
February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852040134627764" on VIMEO

Cast: Sagent Pharmaceuticals... See more »
February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852041194908227" on VIMEO

Cast: Sagent Pharmaceuticals... See more »
February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852048392193338" on VIMEO

Cast: Sagent Pharmaceuticals... See more »
February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852028033207638" on VIMEO

Cast: Sagent Pharmaceuticals... See more »
February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852031763085015" on VIMEO

Cast: Sagent Pharmaceuticals... See more »
February 18, 2016Sagent Pharmaceuticals Vimeo Channel

"final_SAGENT_635852032788321867" on VIMEO

Cast: Sagent Pharmaceuticals... See more »

Social Media

Sagent Pharmaceuticals Headquarters

1901 N Roselle Rd

Schaumburg, Illinois60195

847-908-1600

Driving Directions »

Trending Companies

Sagent Pharmaceuticals Summary

ABOUT

Overview

Sagent Pharmaceuticals focuses on the development and commercialization of injectable pharmaceutical products for cancer, oncology and urology. Sagent Pharmaceuticals was founded in 2006. Sagent Pharmaceuticals' headquarters is located in Schaumburg, ...

CEO

Sagent Pharmaceuticals's CEO, Peter Kaemmerer, currently has an approval rating of 68%. Sagent Pharmaceuticals's primary competitors are Bausch Health, Sun Pharma & Sandoz.

Frequently Asked Questions about Sagent Pharmaceuticals

  1. When was Sagent Pharmaceuticals founded?

    Sagent Pharmaceuticals was founded in 2006
  2. Who is Sagent Pharmaceuticals's CEO?

    Sagent Pharmaceuticals's CEO is Peter Kaemmerer
  3. How much revenue does Sagent Pharmaceuticals generate?

    Sagent Pharmaceuticals generates $297.8M in revenue
  4. How much funding does Sagent Pharmaceuticals have?

    Sagent Pharmaceuticals has historically raised $162M in funding
  1. Where is Sagent Pharmaceuticals's headquarters?

    Sagent Pharmaceuticals's headquarters is in Schaumburg Illinois, USA
  2. How many employees does Sagent Pharmaceuticals have?

    Sagent Pharmaceuticals has 440 employees
  3. Who are Sagent Pharmaceuticals's competitors?

    Sagent Pharmaceuticals's top competitors are Bausch Health, Sun Pharma, Sandoz